Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).
2018 ◽
Vol 36
(15_suppl)
◽
pp. 7515-7515
◽
Keyword(s):
Phase 2
◽
2014 ◽
Vol 55
(8)
◽
pp. 1854-1860
◽